Literature DB >> 17460380

Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test.

Roberto Fogari1, Paola Preti, Annalisa Zoppi, Andrea Rinaldi, Elena Fogari, Amedeo Mugellini.   

Abstract

Primary aldosteronism (PA) has been considered a rare cause of hypertension. The introduction of the aldosterone/renin ratio (ARR) as a screening test has led to an increase in the detection rate. The aim of this study was to evaluate the prevalence of PA among unselected hypertensive patients by using an ARR >25 as a screening test. We studied 3,000 consecutive unselected hypertensive patients. Blood samples for the determination of plasma renin activity (PRA), aldosterone (ALD) and electrolytes were drawn in the morning, and patients with an ARR >25 underwent intravenous saline infusion as a confirmatory test. Adrenal CT and a dexamethasone suppression test were performed in patients with confirmed PA. Patients with a positive dexamethasone test underwent genetic testing for glucocorticoid-remediable aldosteronism (GRA). Out of 3,000 hypertensives, 684 (22.8%) showed an ARR >25 and 177 of them (5.9% of the whole population) had a positive saline loading test. Only 44 of them (24.8%) were hypokalemic. CT was performed in all the patients with confirmed PA and 53 of them (29.9%) had a solitary adrenal macroadenoma, 112 (63.3%) had bilateral adrenal enlargement and 12 (6.8%) had normal appearing adrenal glands. Of 177 patients given dexamethasone to identify GRA, 8 (4.5%) showed aldosterone suppression but only one (0.1%) tested positive for the chimeric gene. In conclusion, our findings indicate that standardized application of an ARR >25 to unselected hypertensive patients, followed by i.v. saline loading as a confirmatory test, can result in the detection of a large number of patients with PA (5.9% of the studied population), most of whom are normokalemic. Bilateral adrenal hypertrophy represents the more common form of PA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460380     DOI: 10.1291/hypres.30.111

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  20 in total

1.  Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups.

Authors:  Guoshu Yin; Shaoling Zhang; Li Yan; Muchao Wu; Mingtong Xu; Feng Li; Hua Cheng
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

Review 2.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

3.  Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function.

Authors:  Il Young Kim; In Seong Park; Min Jeong Kim; Miyeun Han; Harin Rhee; Eun Young Seong; Dong Won Lee; Soo Bong Lee; Ihm Soo Kwak; Sang Heon Song; Hyun Chul Chung
Journal:  Int Urol Nephrol       Date:  2018-05-19       Impact factor: 2.370

4.  Is aldosteronism really a relatively common cause of hypertension?

Authors:  Günther Egidi; Guido Schmiemann; Klaus Gebhardt
Journal:  CMAJ       Date:  2018-04-03       Impact factor: 8.262

Review 5.  Primary aldosteronism is a public health issue: challenges and opportunities.

Authors:  Renata Libianto; Peter J Fuller; Morag J Young; Jun Yang
Journal:  J Hum Hypertens       Date:  2020-04-27       Impact factor: 3.012

Review 6.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

7.  The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.

Authors:  Chin-Chi Kuo; Poojitha Balakrishnan; Yenh-Chen Hsein; Vin-Cent Wu; Shih-Chieh Jeff Chueh; Yung-Ming Chen; Kwan-Dun Wu; Ming-Jiuh Wang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-07-16       Impact factor: 1.636

8.  Persistent hypertension after adrenalectomy for an aldosterone-producing adenoma: weight as a critical prognostic factor for aldosterone's lasting effect on the cardiac and vascular systems.

Authors:  Yvette Carter; Madhuchhanda Roy; Rebecca S Sippel; Herbert Chen
Journal:  J Surg Res       Date:  2012-08-15       Impact factor: 2.192

9.  Predictors of successful outcome after adrenalectomy for primary aldosteronism.

Authors:  Wei Wang; WeiLie Hu; XiaoMing Zhang; BangQi Wang; Chen Bin; Hai Huang
Journal:  Int Surg       Date:  2012 Apr-Jun

10.  Prevalence of primary aldosteronism in primary care: a cross-sectional study.

Authors:  Sabine C Käyser; Jaap Deinum; Wim Jc de Grauw; Bianca Wm Schalk; Hans Jhj Bor; Jacques Wm Lenders; Tjard R Schermer; Marion Cj Biermans
Journal:  Br J Gen Pract       Date:  2018-01-15       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.